Editorial
Copyright ©2011 Baishideng Publishing Group Co.
World J Clin Oncol. Dec 10, 2011; 2(12): 377-383
Published online Dec 10, 2011. doi: 10.5306/wjco.v2.i12.377
Table 4 Neoadjuvant chemotherapy trials
TrialPhasePtsStudy designMain end-pointResults
Al-Amro A et al[23]II110Neo cDDP-Epi and followed by cDDP + RTORR100%
Airoldi M et al[24]II30Neo cbdca-Pac followed by RT + cbdca-PacORR87%
Ferrari D et al[25]II34Neo cDDP-5FU followed by RT + cDDPORR85.3%
Lu X et al[26]II58Neo cbdca-Tax followed by cbdca + RT (arm A) vs neo cbdca-5FU followed by cbdca + RT (armB)1-year DFSno difference between arm A and B
Mosatafa E et al[27]II36Neo cDDP-Pac followed by cDDP-RTORR89%
Hui EP et al[28]II65Neo cDDP-Tax followed by cDDP + RT (arm A) vs cDDP + RT (arm B)3-year OSArm A better than arm B (P < 0.012)
Bossi P et al[29]II45Neo cDDP-Tax-5FU followed by cDDP + RTORR98%
Cho S et al[30]II19Neo cDDP-Tax-5FU followed by cDDP + RTORR93%
Bae WK et al[32]II33Neo cDDP-Tax-5FU followed by cDDP + RTORR99%
Kong L et al[6]II52Neo cDDP-Tax-5FU followed by cDDP + RTORR90.2%
Ekenel M et al[34]II59Neo cDDP-Tax followed by cDDP + RTORR95%
Lin S et al[35]II370Neo cDDP based CT followed by IMRT3-year OS90%